Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?-Reference-Cited by-同舟云学术

Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?

Published:2022-01 Issue: Volume:169 Page:103532
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Ambrosini Margherita^ORCID,Fucà Giovanni^ORCID,Duca Matteo^ORCID,Damian Silvia^ORCID,De Santis Francesca,Corti Francesca,Cresta Sara^ORCID,de Braud Filippo,Di Nicola Massimo^ORCID

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference110 articles.

1. Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies;Alexander;Front. Med. (Lausanne),2015

2. Sears RC. Mission possible: advances in MYC therapeutic targeting in Cancer;Allen-Petersen;BioDrugs,2019

3. First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours;Ameratunga;Br. J. Cancer,2020

4. STAT3 in cancer: a double edged sword;Avalle;Cytokine.,2017

5. A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo;Bai;Cancer Cell,2019

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Confounding Factors in Targeted Degradation of Short-Lived Proteins;ACS Chemical Biology;2024-07-03

2. Confounding factors in targeted degradation of short-lived proteins;2024-02-22

3. PROTACs: A novel strategy for cancer drug discovery and development;MedComm;2023-05-29

4. PROTAC: targeted drug strategy. Principles and limitations;Russian Chemical Bulletin;2022-11

5. An MDM2 degrader for treatment of acute leukemias;Leukemia;2022-10-29